Navigation Links
WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
Date:5/27/2008

OAKLAND, Calif., May 27 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) -- World Heart Corporation (the "Company") today announced that on May 20, 2008, it had received a letter from the NASDAQ Hearings Panel stating that they had received the Company's request to appeal the NASDAQ Listing Qualification Staff determination to delist World Heart Corporation's securities from the NASDAQ Stock Market. Accordingly, the delisting action referenced in the NASDAQ Staff's determination letter has been stayed, pending a final written decision by the NASDAQ Hearings Panel.

This letter provided formal notice that the panel will consider our appeal at an oral/written hearing. The hearing will be held on Thursday, July 10, 2008, at 2:30 PM in Washington, DC.

This decision by the NASDAQ Hearings Panel means that the stock will continue to trade at least until the determination is made at this hearing.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
2. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
3. WorldHeart Schedules Teleconference
4. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
7. NicOx Announces Departure of Damian Marron for CEO Position
8. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
9. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
10. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
11. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):